Replimune's Survival Hinges on a Pivotal Pivot After Second FDA Rejection

The clinical-stage biotech Replimune Group, Inc. now faces a fundamental corporate reinvention. Its lead candidate, the oncolytic immunotherapy RP1, has been rejected for a second time by the U.S. Food and Drug Administration, forcing the company into a fight for its future. Shares plummeted 19.5% to $4.76 in regular trading on April 10, 2026, before collapsing a further 63% to $1.75 in after-hours action, a stark contrast to its 52-week high of $13.24.

At the heart of the FDA's repeated refusal is the clinical data package. The agency issued a Complete Response Letter (CRL) for the Biologics License Application for RP1 in combination with nivolumab to treat advanced melanoma. It maintained that the primary supporting study, IGNYTE, does not constitute an adequately controlled clinical investigation. The FDA argued the single-arm Phase 1/2 trial design cannot isolate RP1's specific contribution to the combination's efficacy, a stance it first communicated in an initial CRL back in July 2025.

Replimune submitted supplemental analyses to address the concerns, but the regulator was unmoved. Notably, the FDA deployed a completely new review team for this second submission, yet arrived at the identical conclusion. The agency has emphasized its evidence requirements have been consistently communicated since 2021. Company leadership, including CEO Sushil Patel, forcefully disagrees, contending the regulatory system lacks flexibility for high-unmet-need therapies. They point to a 34% response rate and a median duration of response of 24.8 months from the IGNYTE data, which previously secured a Breakthrough Therapy designation.

The strategic and financial fallout is immediate and severe. Replimune had previously warned in SEC filings that a second rejection would jeopardize the RP1 program's viability. True to that warning, the company announced significant job cuts and a scaling back of U.S. manufacturing capacity just one day after the CRL. These moves reverse substantial pre-commercial infrastructure investments made in anticipation of a launch that will not happen.

Should investors sell immediately? Or is it worth buying Replimune?

Financially, the company's runway is constrained. As of December 31, 2025, Replimune held cash, cash equivalents, and short-term investments of $269.1 million, down significantly from $483.8 million a year earlier. Management believes this provides liquidity into the first quarter of 2027. However, a credit facility with Hercules Capital that could have provided an additional $120 million upon approval is now effectively void. Furthermore, a shelf registration statement filed in November 2025 for up to $250 million, including an at-the-market program for up to $100 million, may now be activated, presenting a critical near-term decision for the board.

With the accelerated approval pathway firmly closed, Replimune's sole remaining regulatory route for RP1 is the ongoing randomized Phase 3 trial, IGNYTE-3, which is also testing RP1 with Opdivo (nivolumab). This study's primary endpoint is overall survival, with an estimated completion date of January 2029. At the time of the FDA's latest review, only about ten percent of the planned patient population had been treated, providing insufficient data. The company has stated the RP1 program is not sustainable without an accelerated approval, raising questions about the pace and funding of IGNYTE-3 recruitment going forward.

Other clinical programs, such as the RP2 REVEAL study in metastatic uveal melanoma involving approximately 280 patients, continue. The extent to which the new cost-cutting measures will impact these efforts remains unclear.

Replimune at a turning point? This analysis reveals what investors need to know now.

Wall Street analysts are compelled to overhaul their models entirely. Prior to the second CRL, the average price target among the seven analysts covering Replimune stood at $12.86, implying 116% upside. Four analysts rated the stock a "Buy," with one issuing a "Strong Buy" recommendation. These optimistic stances are now obsolete. The narrative must shift from an imminent commercial story to a multi-year, trial-driven venture operating on a finite cash reserve. For Replimune, the struggle is no longer about securing approval for RP1; it is about proving the company itself can survive long enough to generate new data.

Ad

Replimune Stock: New Analysis - 12 April

Fresh Replimune information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Replimune analysis...

en | US76029N1063 | REPLIMUNES | boerse | 69132279 |